Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Bull-like who wrote (597)	3/23/1999 1:20:00 AM
From: Anthony Wong	Respond to of 942

Bull, I don't think Rezulin would be taken off the market either. That's only the worst case scenario. The best time to buy is when analysts downgrade and blood is on the street. Stock would be weak in the near term. The same scenario was played last year when Glaxo-Welcome took the drug off the market in the UK.

To: Bull-like who wrote (597)	3/23/1999 10:39:00 AM
From: Anthony Wong	Respond to of 942

Warner-Lambert Reiterated 'Buy' at Credit Suisse First Bloomberg News March 23, 1999, 9:24 a.m. ET Princeton, New Jersey, March 23 (Bloomberg Data) -- Warner-Lambert Co. (WLA US) was reiterated ''buy'' by analyst James A. Kelly at Credit Suisse First Boston Inc. The 12-month target price is $85.00 per share. -- Michael O. Donohue in Princeton, New Jersey, (609)279-3156 (Story illustration: For a chart of the company's stock prices, see WLA US GP D. For more company news and information, see WLA US BR, BQ, CN, COMP, TRA. For more country and industry news, see NI DRG, NI HOU, NI NJ, NI US, NI ANA. For more rating changes, see BBSA2) -0- ( ) Mar/23/ 99 9:24 N ) M

To: Bull-like who wrote (597)	3/23/1999 10:44:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

Warner-Lambert Reiterated Short-Term 'Outperform' at Everen Bloomberg News March 23, 1999, 10:30 a.m. ET Princeton, New Jersey, March 23 (Bloomberg Data) -- Warner-Lambert Co. (WLA US) was reiterated short-term ''outperform'' by analyst Jeffrey J. Kraws at Everen Securities. The long-term rating was also reiterated ''outperform.'' The intermediate and long-term price targets are $88 and $94. per share, respectively. -- Donna McDonald in Princeton, New Jersey, (609)279-3731 (Story illustration: For a chart of the company's stock prices, see WLA US GP D. For more company news and information, see WLA US BR, BQ, CN, COMP, TRA. For more country and industry news, see NI DRG, NI HOU, NI NJ, NI US, NI ANA. For more rating changes, see BBSA2) -0- ( ) Mar/23/ 99 10:30